Federal Register / Vol. 82, No. 165 / Monday, August 28, 2017 / Notices 40769 

and Receiverships, Attention: 

Receivership Oversight Department 

34.6, 1601 Bryan Street, Dallas, TX 

75201. 

No comments concerning the 

termination of this receivership will be 

considered which are not sent within 

this time frame. 

Dated: August 23, 2017. 

Federal Deposit Insurance Corporation. 

Robert E. Feldman, 

Executive Secretary. 

[FR Doc. 2017–18156 Filed 8–25–17; 8:45 am] 

BILLING CODE 6714–01–P 

FEDERAL DEPOSIT INSURANCE 

CORPORATION 

Notice to All Interested Parties of the 

Termination of the Receivership of 

10301—First Suburban National Bank, 

Maywood, Illinois 

Notice is hereby given that the Federal 

Deposit Insurance Corporation (FDIC) as 

Receiver for First Suburban National 

Bank, Maywood, Illinois (‘‘the 

Receiver’’) intends to terminate its 

receivership for said institution. The 

FDIC was appointed Receiver of First 

Suburban National Bank on October 22, 

2010. The liquidation of the 

receivership assets has been completed. 

To the extent permitted by available 

funds and in accordance with law, the 

Receiver will be making a final dividend 

payment to proven creditors. 

Based upon the foregoing, the 

Receiver has determined that the 

continued existence of the receivership 

will serve no useful purpose. 

Consequently, notice is given that the 

receivership shall be terminated, to be 

effective no sooner than thirty days after 

the date of this notice. If any person 

wishes to comment concerning the 

termination of the receivership, such 

comment must be made in writing and 

sent within thirty days of the date of 

this notice to: Federal Deposit Insurance 

Corporation, Division of Resolutions 

and Receiverships, Attention: 

Receivership Oversight Department 

34.6, 1601 Bryan Street, Dallas, TX 

75201. 

No comments concerning the 

termination of this receivership will be 

considered which are not sent within 

this time frame. 

Dated August 22, 2017. 

Federal Deposit Insurance Corporation. 

Robert E. Feldman, 

Executive Secretary. 

[FR Doc. 2017–18109 Filed 8–25–17; 8:45 am] 

BILLING CODE 6714–01–P 

DEPARTMENT OF DEFENSE 

GENERAL SERVICES 

ADMINISTRATION 

NATIONAL AERONAUTICS AND 

SPACE ADMINISTRATION 

[OMB Control No. 9000–0180; Docket No. 

2017–0053; Sequence 12] 

Information Collection; Affirmative 

Procurement of Biobased 

Procurements Under Services and 

Construction Contracts 

AGENCY: Department of Defense (DOD), 

General Services Administration (GSA), 

and National Aeronautics and Space 

Administration (NASA). 

ACTION: Notice of request for public 

comments regarding an extension to an 

existing OMB clearance. 

SUMMARY: Under the provisions of the 

Paperwork Reduction Act, the 

Regulatory Secretariat Division (MVCB) 

will be submitting to the Office of 

Management and Budget (OMB) a 

request to review and approve an 

extension of a previously approved 

information collection requirement 

regarding Biobased Procurements. 

DATES: Submit comments on or before 

October 27, 2017. 

ADDRESSES: Submit comments 

identified by Information Collection 

9000–0180, Affirmative Procurement of 

Biobased Procurements Under Services 

and Construction Contracts, by any of 

the following methods: 

• Regulations.gov: http://

www.regulations.gov. Submit comments 

via the Federal eRulemaking portal by 

searching the OMB control number 

9000–0180. Select the link ‘‘Comment 

Now’’ that corresponds with 

‘‘Information Collection 9000–0180, 

Affirmative Procurement of Biobased 

Procurements Under Services and 

Construction Contracts. Follow the 

instructions provided on the screen. 

Please include your name, company 

name (if any), and ‘‘Information 

Collection 9000–0180, ‘‘Affirmative 

Procurement of Biobased Procurements 

Under Services and Construction 

Contracts’’ on your attached document. 

• Mail: General Services 

Administration, Regulatory Secretariat 

Division (MVCB), 1800 F Street NW., 

Washington, DC 20405. ATTN: Ms. 

Sosa/IC 9000–0180, Biobased 

Procurements. 

Instructions: Please submit comments 

only and cite Information Collection 

9000–0180, Affirmative Procurement of 

Biobased Procurements Under Services 

and Construction Contracts. Comments 

received generally will be posted 

without change to http://

www.regulations.gov, including any 

personal and/or business confidential 

information provided. To confirm 

receipt of your comment(s), please 

check www.regulations.gov, 

approximately two to three days after 

submission to verify posting (except 

allow 30 days for posting of comments 

submitted by mail). 

FOR FURTHER INFORMATION CONTACT: Mr. 

Charles Gray, Procurement Analyst, 

Office of Governmentwide Acquisition 

Policy, at telephone 703–795–6328, or 

email charles.gray@gsa.gov. 

SUPPLEMENTARY INFORMATION: 

A. Purpose 

Federal Acquisition Regulation clause 

52.223–2, Affirmative Procurement of 

Biobased Products Under Service and 

Construction Contracts, requires prime 

contractors to report annually the 

product types and dollar values of U.S. 

Department of Agriculture (USDA)- 

designated biobased products purchased 

to the System for Award Management 

(SAM) Web site. The information 

reported by prime contractors enables 

Federal agencies to report annually to 

the Office of Federal Procurement 

Policy (OFPP) concerning actions taken 

to implement and measure progress in 

carrying out the preference for biobased 

products required under section 9002 of 

the Farm Security and Rural Investment 

Act of 2002, codified at 7 U.S.C. 8102. 

B. Annual Reporting Burden 

To determine the number of 

contractors performing construction and 

service contracts that may involve the 

purchase of USDA-designated biobased 

products, fiscal year 2016 data in the 

Federal Procurement Data System 

(FPDS) was reviewed to calculate the 

number entities with unique DUNS 

numbers that were awarded contracts 

for the following selected Product 

Services Codes: A—Research and 

Development; F—Natural Resources 

Management; J—Maintenance, Repair, 

and Rebuilding of Equipment; M— 

Operation of Government-Owned 

Facility; S—Utilities and Housekeeping 

Services; T—Photographic, Mapping, 

Printing, and Publication Services; Y— 

Construction of Structures and 

Facilities; and Z—Maintenance, Repair 

or Alteration of Real Property. The 

clause at FAR 52.223–2 will apply to the 

majority of the contract actions in the 

selected PSCs 

The estimated total burden is as 

follows: 

Respondents: 51,457. 

Responses per Respondent: 5. 

Total Annual Responses: 257,285. 


asabaliauskas on DSKBBXCHB2PROD with NOTICES
40770 Federal Register / Vol. 82, No. 165 / Monday, August 28, 2017 / Notices 

Hours per Response: 5. 

Total Burden Hours: 1,286,425. 

Affected Public: Businesses or other 

for-profit and not-for-profit institutions. 

Frequency: Annually. 

C. Public Comments 

Public comments are particularly 

invited on: Whether this collection of 

information is necessary for the proper 

performance of functions of the FAR, 

and whether it will have practical 

utility; whether our estimate of the 

public burden of this collection of 

information is accurate, and based on 

valid assumptions and methodology; 

ways to enhance the quality, utility, and 

clarity of the information to be 

collected; and ways in which we can 

minimize the burden of the collection of 

information on those who are to 

respond, through the use of appropriate 

technological collection techniques or 

other forms of information technology. 

Obtaining Copies of Proposals: 

Requesters may obtain a copy of the 

information collection documents from 

the General Services Administration, 

Regulatory Secretariat Division (MVCB), 

1800 F Street NW., Washington, DC 

20405, telephone 202–501–4755. Please 

cite OMB Control No. 9000–0180, 

Affirmative Procurement of Biobased 

Procurements Under Services and 

Construction Contracts, in all 

correspondence. 

Dated: August 22, 2017. 

Lorin S. Curit, 

Director, Federal Acquisition Policy Division, 

Office of Government-wide Acquisition 

Policy, Office of Acquisition Policy, Office 

of Government-wide Policy. 

[FR Doc. 2017–18105 Filed 8–25–17; 8:45 am] 

BILLING CODE 6820–EP–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2017–N–0001] 

Cellular, Tissue, and Gene Therapies 

Advisory Committee; Notice of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) announces a 

forthcoming public advisory committee 

meeting of the Cellular, Tissue, and 

Gene Therapies Advisory Committee 

(CTGTAC). The general function of the 

committee is to provide advice and 

recommendations to the Agency on 

FDA’s regulatory issues. The meeting 

will be open to the public. 

DATES: The meeting will be held on 

October 12, 2017, from 8:30 a.m. to 5 

p.m. 

ADDRESSES: FDA White Oak Campus, 

10903 New Hampshire Ave., Bldg. 31 

Conference Center, the Great Room (Rm. 

1503) Silver Spring, MD 20993–0002. 

For those unable to attend in person, 

the meeting will also be Webcast and 

will be available at the following link: 

https://collaboration.fda.gov/ 

ctgtac101217. Answers to commonly 

asked questions including information 

regarding special accommodations due 

to a disability, visitor parking, and 

transportation may be accessed at: 

https://www.fda.gov/ 

AdvisoryCommittees/ 

AboutAdvisoryCommittees/ 

ucm408555.htm. 

FOR FURTHER INFORMATION CONTACT: 

Prabhakara L. Atreya or Denise Royster, 

Center for Biologics Evaluation and 

Research, Food and Drug 

Administration, 10903 New Hampshire 

Ave., Bldg. 71, Rm. 6306, Silver Spring, 

MD 20993–0002, 240–402–8006, 

prabhakara.atreya@fda.hhs.gov and 

240–402–8158, denise.royster@

fda.hhs.gov, or FDA Advisory 

Committee Information Line, 1–800– 

741–8138 (301–443–0572 in the 

Washington, DC area). A notice in the 

Federal Register about last minute 

modifications that impact a previously 

announced advisory committee meeting 

cannot always be published quickly 

enough to provide timely notice. 

Therefore, you should always check the 

Agency’s Web site at https://

www.fda.gov/AdvisoryCommittees/ 

default.htm and scroll down to the 

appropriate advisory committee meeting 

link, or call the advisory committee 

information line to learn about possible 

modifications before coming to the 

meeting. 

SUPPLEMENTARY INFORMATION: 

Agenda: On October 12, 2017, the 

CTGTAC will meet in an open session 

to discuss and make recommendations 

on the safety and effectiveness of 

biologics license application (BLA) for 

voretigene neparvovec (BLA 125610), 

submitted by Spark Therapeutics, Inc. 

The proposed indication (use) for this 

product is for the treatment of patients 

with vision loss due to confirmed 

biallelic RPE65 mutation-associated 

retinal dystrophy. 

FDA intends to make background 

material available to the public no later 

than 2 business days before the meeting. 

If FDA is unable to post the background 

material on its Web site prior to the 

meeting, the background material will 

be made publicly available at the 

location of the advisory committee 

meeting, and the background material 

will be posted on FDA’s Web site after 

the meeting. Background material is 

available at https://www.fda.gov/ 

AdvisoryCommittees/Calendar/ 

default.htm. Scroll down to the 

appropriate advisory committee meeting 

link. 

Procedure: Interested persons may 

present data, information, or views, 

orally or in writing, on issues pending 

before the committee. Written 

submissions may be made to the contact 

person on or before October 4, 2017. 

Oral presentations from the public will 

be scheduled between approximately 

11:15 a.m. and 12:15 p.m. Those 

individuals interested in making formal 

oral presentations should notify the 

contact person and submit a brief 

statement of the general nature of the 

evidence or arguments they wish to 

present, the names and addresses of 

proposed participants, and an 

indication of the approximate time 

requested to make their presentation on 

or before September 26, 2017. Time 

allotted for each presentation may be 

limited. If the number of registrants 

requesting to speak is greater than can 

be reasonably accommodated during the 

scheduled open public hearing session, 

FDA may conduct a lottery to determine 

the speakers for the scheduled open 

public hearing session. The contact 

person will notify interested persons 

regarding their request to speak by 

September 27, 2017. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

Agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with disabilities. 

If you require accommodations due to a 

disability, please contact Prabhakara 

Atreya at least 7 days in advance of the 

meeting. 

FDA is committed to the orderly 

conduct of its advisory committee 

meetings. Please visit our Web site at: 

https://www.fda.gov/ 

AdvisoryCommittees/ 

AboutAdvisoryCommittees/ 

ucm111462.htm for procedures on 

public conduct during advisory 

committee meetings. 

Notice of this meeting is given under 

the Federal Advisory Committee Act (5 

U.S.C. app. 2). 


asabaliauskas on DSKBBXCHB2PROD with NOTICES